Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Sialyl Lewis x expression in canine malignant mammary tumours: correlation with clinicopathological features and E-Cadherin expression

  • Salomé S Pinho1, 2,
  • Augusto JF Matos2,
  • Célia Lopes2,
  • Nuno T Marcos1,
  • Júlio Carvalheira2,
  • Celso A Reis1, 3 and
  • Fátima Gärtner1, 2Email author
BMC Cancer20077:124

https://doi.org/10.1186/1471-2407-7-124

Received: 02 January 2007

Accepted: 06 July 2007

Published: 06 July 2007

Abstract

Background

Sialyl Lewis x (sLex) antigen is a carbohydrate antigen that is considered not only a marker for cancer but also implicated functionally in the malignant behaviour of cancer cells. Overexpression of sLex is associated with enhanced progression and metastases of many types of cancer including those of the mammary gland. Canine mammary tumours can invade and give rise to metastases via either lymphatic or blood vessels.

E-Cadherin is specifically involved in epithelial cell-to-cell adhesion. In cancer, E-Cadherin underexpression is one of the alterations that characterizes the invasive phenotype and is considered an invasion/tumour suppressor gene. Partial or complete loss of E-Cadherin expression correlates with poor prognosis in canine malignant mammary cancer.

The aim of this study was to analyse the sLex expression in canine malignant mammary tumours and to evaluate if the presence of sLex correlates with the expression of E-Cadherin and with clinicopathological features.

Methods

Fifty-three cases of canine mammary carcinomas were analysed immunohistochemically using monoclonal antibodies against sLex (IgM) and E-Cadherin (IgG). The clinicopathological data were then assessed to determine whether there was a correlation with sLex tumour expression. Double labelled immunofluorescence staining was performed to analyse the combined expression of sLex and E-Cadherin.

Results

sLex expression was consistently demonstrated in all cases of canine mammary carcinomas with different levels of expression. We found a significant relationship between the levels of sLex expression and the presence of lymph node metastases. We also demonstrated that when E-Cadherin expression was increased sLex was reduced and vice-versa. The combined analysis of both adhesion molecules revealed an inverse relationship.

Conclusion

In the present study we demonstrate the importance of sLex in the malignant phenotype of canine malignant mammary tumours. Our results support the use of sLex as a prognostic tumour marker in canine mammary carcinomas. Furthermore, we showed that sLex and E-Cadherin expression were inversely correlated. Future studies are warranted to clarify the molecular mechanism underlying the relation between sLex and E-Cadherin in canine mammary carcinoma cells which represents an important comparative model to woman breast cancer.

Background

Mammary tumours are the most common tumours in intact female dogs and approximately 40% to 50% of these tumours are malignant [1]. All malignant canine mammary tumours have the potential to metastasise. In general canine malignant tumours metastasise via the lymphatics to the regional lymph nodes or hematogenously to the lungs that represent the most common site of distant metastases. [13]

Malignant transformation is associated with abnormal glycosylation, resulting in expression of altered carbohydrate determinants, such as the Sialyl Lewis x (sLex) antigen. Altered cell surface glycosylation is a prominent feature of malignant tumour cells and define their invasive and/or metastatic properties in general [412].

Tumour metastasis is a multistep process requiring detachment of malignant cells from the primary tumour, invasion of blood or lymph vessels, interaction with endothelium, extravasation at distant sites and formation of new tumour foci [9, 12, 13]. It is generally accepted that every step of the metastatic cascade is dependent on specific adhesive interactions of cancer cells with other cells and components of the extracellular matrix. These interactions are mediated by different families of adhesion molecules including cadherins, integrins, members of the immunoglobulin superfamily, and selectins and their carbohydrate ligands – Sialyl Lewis a (sLea) and sLex [9, 13, 14].

sLex is a tetrasaccharide (NeuAcα2 → 3Galβ1 → 4[Fucα1 → 3]GlcNAcβ1 → R) that is particularly relevant from a biological standpoint. It is involved in selectin-mediated adhesion of cancer cells to vascular endothelium and this determinant is thought to be closely associated with hematogenous metastases of cancer [1217]

In humans, the expression of sLex is significantly increased in carcinoma cells [4, 7, 18]. Many clinical studies have shown an association between the expression of sLex on tumours and enhanced tumour progression and metastasis [7, 19]. In woman breast carcinoma the presence of sLex was also correlated with poor prognosis [20, 21]. In fact, the presence of sLex has been used as a prognostic tumour marker in various types of human cancer [7, 19], e.g. lung [22], bladder [8], breast [20, 21, 23], prostate [24], colon [25] and gastric [2628] carcinoma. Little is known about the expression of sLex in canine tumours. To the best of our knowledge only the study of Nakagawa et al describe the expression of sLex in canine and feline mammary gland tumours [29], but no significant correlation between the expression of sLex and prognosis has been described in canine or feline tumours.

sLex and E-cadherin are two adhesion molecules that seem to be involved in malignant progression with opposite roles [31]. Alpaugh et al have described a cooperative role between E-cadherin and sLex in the passive dissemination of tumour emboli and in the genesis of the lymphovascular embolus of woman's Inflammatory Breast Carcinoma [3032].

Recently, Jeschke et al identified a negative correlation between Sialyl Lewis antigens and E-cadherin expression in woman breast cancer and their lymph node metastases [23]. This combined analysis of tumour antigens involved in adhesion of breast cancer cells has never been described in canine mammary tumours, which constitutes an important comparative model for woman breast cancer.

The purpose of the present study is to analyse, by immunohistochemical staining methods, the expression of the carbohydrate sLex in canine malignant mammary tumours and to evaluate the relationship between sLex expression and tumour clinicopathological features. The relation between the expression of the molecules sLex and E-Cadherin [33] in canine malignant mammary tumours was also investigated.

Methods

Tissue specimens

Fifty-three malignant mammary tumours and 102 local and regional lymph nodes were surgically removed from 35 female dogs aged from 3 to 16 (mean, 9.9 years), of various pure or mixed breeds. The specimens were fixed in 10% neutral buffered formalin. After dehydration and paraffin wax embedment, sections of 4 μm were cut from each representative paraffin blocks for staining with haematoxylin and eosin (HE) and for sLex and E-cadherin immunohistochemistry (IHC).

Lymph nodes were classified according to the presence of cancer cells (positive or negative), using HE and cytokeratin IHC methods [33].

Histological examination of the tumours

Tumours, including benign proliferative lesions found in the vicinity of the tumours, were classified independently by two observers from HE-stained sections on the basis of the diagnostic criteria of the World Health Organization classification of tumours in domestic animals [34].

The presence of intra-tumoral necrosis was registered for each case and evaluation and classification of the mode of tumour growth was assessed as previously described [33].

Follow-up data

All animals were clinically evaluated every 3 months (by physical examination, thoracic radiography and abdominal ultrasound) for the presence of distant metastases during a follow-up period of 2 years after surgery. All dogs were followed until death or until the end of the observation period. In all dogs that died with suspected distant metastases, complete necropsies were performed and histological confirmation was obtained.

Immunohistochemistry

Canine mammary cancer tissues, which had been resected by the curative operation were routinely processed and used for immunostaining of sLex and E-cadherin.

Immunostaining was performed by the modified avidin-biotin-peroxidase complex (ABC) method [35]. Two distinct monoclonal antibodies (mAbs) were used: the mAb FH6 generated against sLex epitope [36] and the monoclonal mouse anti-human E-cadherin antibody (clone 4A2C7, Zymed, S.Francisco, California, USA) [33].

Tumour sections (4 um thick) were deparaffinized in xylene, dehydrated through graded concentrations of ethanol and washed with distilled water. Sections were then treated with Citrate buffer (sodium citrate antigen retrieval solution; 10 mM citric acid, pH = 6) for 20 minutes in a microwave oven at 600 W. The slides were cooled for 10 minutes at room temperature and rinsed twice in Phosphate buffered saline (PBS) for 5 minutes. Endogenous peroxidase activity was blocked by treating the section with hydrogen peroxide 3% in methanol for 10 min. After washing the slides in PBS, non-specific staining was eliminated by incubating the sections with normal rabbit serum (Dako) diluted at 1:5 in PBS containing bovine serum albumin (BSA) 10%, in a humid chamber for 20 min at room temperature. Excess normal serum was removed and replaced by the anti-sLex mAb FH6 diluted at 1:5. After overnight incubation (18 hours) at 4°C, slides were washed with PBS and incubated for 30 min with a 1:200 dilution of biotin-labelled rabbit anti-mouse secondary antibody (Dako). Sections were then washed with PBS and incubated for 30 min with avidin-biotin complex (Dako) diluted at 1:100. This was followed by staining the sections for 5 to 7 minutes with 0.05% 3,3 diaminobenzidinetetrahydrochloride (DAB) freshly prepared in 0.05 M Tris/hydroxymethylaminomethane buffer, pH 7.6, containing 0.1% hydrogen peroxide. Finally, sections were lightly counterstained with haematoxylin, dehydrated, and mounted.

Dilution of primary antibody, biotin-labelled secondary antibody, and avidin-biotin complex were made with PBS containing 5% BSA.

All series included, as positive control sections of a human mixed gastric carcinoma previously shown to display prominent expression of sLex.

Negative controls were performed by substitution of the primary antibody with immunoglobulins of the same subclass and concentration as the monoclonal antibody.

Scoring of immunostaining and statistical analysis

The degree of mAb FH6 reactivity with individual tissue sections was scored by percentage of stained carcinoma cells in the section by three authors (S.S.P., C.A.R., F.G.) without knowing patients outcome and clinicopathological features of the case. In the event of disagreement, slides were reviewed by the observers, and a consensus was obtained.

Expression of sLex and E-cadherin [33] in canine mammary carcinomas were classified in the following manner: negative, no immunoreactivity or immunostaining in very rare cells; less than 25% of cancer cells stained; 25–50%, well defined areas with positive cells; 50–75% of cancer cells stained; and more than 75% stained cells. Scoring of immunoreactivity was evaluated irrespectively of localization of positive cells and intensity of the staining.

For statistical analysis the expression of sLex was regrouped in two percentual categories (<25% and ≥25%) in order to increase the number of cases in each category and in this manner improve the statistical power of the tests.

The statistical relationship among variables was analysed using tables of frequencies and their significance tested by the Fisher's exact test [37]. P values less than 0.05 were considered a significant association.

Double-labelling Immunofluorescence

For simultaneous visualization of sLex and E-cadherin on the same tissue section, double-label immunofluorescence was performed. We chose the following representative tissue sections: sections with <25% sLex and >75% E-Cadherin expression; sections with >75% sLex and <25% E-Cadherin expression and sections with the same percentage of positive cells for both mAbs.

Paraffin sections were dewaxed, rehydrated and then treated with Extran (Merck, Frankfurt, Germany) 0.05% in distilled water for 10 min in a microwave oven at 750 W. After cooled for 20 min at room temperature, slides were rinsed twice in Phosphate-buffered saline (PBS) and then incubated for 20 min in a humid chamber with rabbit non-immune serum at a dilution 1:5 in PBS containing bovine serum albumin (BSA) 10%. Sections were incubated with the first primary mAb, anti-human E-Cadherin (clone 36, BD Biosciences Pharmigen, diluted 1:100 in PBS), overnight at 4°C. After washing twice for 5 min in PBS, sections were incubated with FITC-conjugated rabbit anti-mouse immunoglobulin (code F261; Dako, Glostrup, Denmark; diluted 1:100 in PBS). Sections were washed two times for 5 min in PBS and blocked with non-immune goat serum diluted 1:5 in PBS containing BSA 10%. Sections were then incubated with mAb FH6 (mouse IgM) diluted at 1:5, overnight at 4°C. Sections were washed two times for 5 min with PBS and incubated with Texas red-conjugated goat anti-mouse IgM (Jackson Immunoresearch) diluted 1:50 in PBS. Sections were washed as before and nuclei were counterstained with 4'-6-Diamidino-2-phenylindole (DAPI, Sigma) for 15 min in the dark, diluted at 1:100 in PBS. Sections were washed two times for 5 min in PBS and mounted with Vectashield (Vector Laboratories, Burlingame, USA).

Dilutions of primary antibodies, secondary antibodies, and DAPI were made with PBS containing 5% BSA.

Microscopy and image processing

Immunostained slides were examined under a fluorescence microscope (Leica DMIRE2) equipped with appropriate filters. Separate images for DAPI, Texas-Red and FITC staining were captured digitally at ×200 and ×400 magnification. The red (for Texas-Red), blue (for DAPI), and green (for FITC) components were merged and composite images were imported into Adobe Photoshop 7.0®.

Results

Clinical and pathological features of mammary carcinoma patients

All dogs that were included in this study were female. The mean age at surgery was 9.9 years old (range: 3–16 years old). Histological diagnosis of canine mammary carcinomas consisted of 2 in situ carcinomas, 13 complex carcinomas, 13 tubulopappilary carcinomas, 9 solid carcinomas, 1 spindle cell carcinoma, 3 mucinous carcinomas, 10 carcinosarcomas and 2 carcinomas in benign tumour.

The mode of tumour growth was assessed in all of 53 tumours. Invasive tumours were more prevalent (28 cases, 52.8%) followed by expansive tumours (17 cases, 32.1%) and tumours with vessel invasion (8 cases, 15.1%).

Lymph node metastases were evaluated in 50 tumours (in 3 cases the regional lymph nodes were not submitted). The majority of the cases did not show lymph node metastases (39, 78.0%) whereas eleven patients (22.0%) revealed metastases in regional lymph nodes. The majority of the cases that showed lymph node metastases were classified as carcinosarcomas (6 out of 11). The others were classified as complex carcinoma, tubulopapillary carcinoma and solid carcinoma. From the eleven cases that revealed nodal metastases, 4 patients revealed in addition, distant metastases. Seven patients with lymph node metastases died (in 4 animals was performed euthanasia because of the tumour and 3 animals died of other causes).

The presence of intra-tumoral necrosis was observed in thirty tumours (56.6%), whereas 23 (43.4%) tumours did not show this feature.

Of the 35 dogs that were included in this study, 33 completed the follow-up period and ten dogs (30.3%) developed distant metastases. From the 17 dogs that died at the end of the follow-up period, 52,9% died because of the mammary carcinoma and 47,0% died from other causes.

Expression of Sialyl Lewis x in canine mammary carcinomas

All of the carcinomas studied by immunohistochemistry showed expression of sLex antigen (Figure 1). Thirty two (60.4%) were found to express sLex in less than 25% of the cells, whereas 21 (39.6%) showed sLex expression in more than 25% of the cells. This distribution of sLex expression include the early stage cases of canine mammary carcinomas such as in situ carcinoma and carcinoma in benign tumour (Table 1). The staining was observed in the cytoplasm and/or in the cell membrane of epithelial cells. In tumour areas with cellular squamous differentiation, sLex was always expressed (Figure 2). In all cases, the adjacent normal mammary gland tissue and the adjacent benign proliferative lesions were evaluated and they did not showed expression of sLex. It was analysed a total of 43 adjacent benign proliferative lesions (6 simple adenomas, 8 epithelioses and the others were hyperplasias in general). In proliferative lesions sLex was expressed only in mammary gland secretion.
Figure 1

Immunohistochemical study of the expression of Sialyl Lewis x in canine malignant mammary tumours. A. Solid carcinoma; >75% of sLex expression; ×400 B. Carcinosarcoma; 25–50% of cells stained; ×400.

Table 1

Relationship between Sialyl Lewis x expression and clinicopathological features in canine malignant mammary tumours.

  

Sialyl Lewis x expression

 

Clinical Features

Number of cases(%)

<25%

≥25%

P value

Histological type (n = 53)

   

NS(0,075)

   In situ carcinoma

2 (3.8%)

1 (50.0%)

1 (50.0%)

 

   Complex carcinoma

13 (24.5%)

12 (92.3%)

1 (7.7%)

 

   Tubulopapillary carcinoma

13 (24.5%)

7 (53.8%)

6 (46.2%)

 

   Solid carcinoma

9 (17.0%)

5 (55.6%)

4 (44.4%)

 

   Spindle cell carcinoma

1 (1.9%)

1 (100.0%)

0 (0.0%)

 

   Mucinous carcinoma

3 (5.7%)

1 (33.3%)

2 (66.7%)

 

   Carcinosarcoma

10 (18.9%)

4 (40.0%)

6 (60.0%)

 

   Carcinoma in benign tumour

2 (3.8%)

1 (50.0%)

1 (50.0%)

 

Mode of Growth (n = 53)

   

NS(0,27)

   Expansive

17 (32.1%)

13 (76.5%)

4 (23.5%)

 

   Invasive

28 (52.8%)

15 (53.6%)

13 (46.4%)

 

   Vessel invasion

8 (15.1%)

4 (50.0%)

4 (50.0%)

 

Lymph node metastases (n = 50)*

   

0.034

   No

39 (78.0%)

29 (74.4%)

10 (25.6%)

 

   Yes

11 (22.0%)

4 (36.4%)

7 (63.6%)

 

Necrosis (n = 53)

   

NS(0,078)

   Absent

23 (43.4%)

17 (73.9%)

6 (26.1%)

 

   Present

30 (56.6%)

15 (50.0%)

15 (50.0%)

 

Distant Metastasis (n = 33)

   

NS(0,24)

   No

23 (69.7%)

17 (73.9%)

6 (26.1%)

 

   Yes

10 (30.3%)

5 (50.0%)

5 (50.0%)

 

* No lymph nodes were submitted with 3 tumours

NS – Not significant (P > 0.05)

Figure 2

Immunohistochemical expression of Sialyl Lewis x in squamous metaplasia. All cells that exhibit squamous metaplasia (arrows) are positive for Sialyl Lewis x. ×400

Relationship between Sialyl Lewis x expression and clinicopathological features

Table 1 summarizes the expression of sLex according to clinicopathological features.

No significant relationship was found between the expression of sLex antigen and the different histological types of canine mammary carcinoma according to the World Health Organization classification of tumours in domestic animals [34].

Similarly, no significant relationship was observed between sLex expression and the growth pattern of mammary carcinomas.

A total of 63.6% of tumours with lymph node metastases showed significantly higher sLex expression (≥25%), whereas most (74.4%) of the tumours without lymph node metastasis showed underexpression (<25%) of sLex (p = 0.034).

Although this association did not reach a statistical significance, we observed that tumours without necrosis showed less sLex expression than tumours with necrosis (p = 0.07).

No significant relationship was found between the expression of sLex antigen and distant metastases.

Relationship between Sialyl Lewis x and E-cadherin expression

The analysis of expression of sLex and E-cadherin disclosed an inverse correlation among the two molecules, higher sLex expression was accompanied with lower E-cadherin expression and vice-versa (Figure 3). When mammary carcinomas show underexpression of E-cadherin (<25%), all of them simultaneously revealed a higher sLex expression (≥25%). On the other hand when tumour samples showed overexpression of E-cadherin (>75%) the majority of them (93.1%) simultaneously revealed less than 50% of sLex expression. In summary, we found a significant relationship (p = 0.013) between sLex and E-cadherin expression in canine malignant mammary tumours (Table 2).
Figure 3

Relation between Sialyl Lewis x and E-cadherin expression. The figure illustrates the negative correlation between sLex and E-Cadherin expression in canine malignant mammary tumours. When expression of E-cadherin increase, the expression of sLex decrease and vice-versa.

Table 2

Relationship between Sialyl Lewis x and E-cadherin expression in canine malignant mammary tumours.

  

Sialyl Lewis x expression

 

E-Cadherin expression

Number of cases (%)

<25%

≥25%

P value

<25%

5 (9.4%)

0 (0.0%)

5 (100.0%)

0.013

25–50%

7 (13.2%)

6 (85.7%)

1 (14.3%)

 

50–75%

12 (22.6%)

9 (75.0%)

3 (25.0%)

 

>75%

29 (54.7%)

17 (58.6%)

12 (41.4%)

 
Simultaneous expression of sLex and E-cadherin was analysed using double-label immunofluorescence method (Figure 4), demonstrating the absence of overlapping between the two molecules (Figure 4). Based on these results, it seems that, when cells express sLex they do not express E-cadherin, and on the other hand when they are positive for E-cadherin they are negative for sLex.
Figure 4

Double-label immunofluorescence of canine malignant mammary tumour (Complex carcinoma). A – Cells that are positive for Sialyl Lewis x (red) are negative for E-cadherin (green) and vice-versa. ×200 B – Absence of co-expression of sLex and E-cadherin in the same cells. ×400

Discussion

Malignant transformation of tumour cells is associated with abnormal glycosylation, resulting in expression of altered carbohydrate determinants including the expression of sLex and sLea antigens [4, 9, 12]. These carbohydrate antigens have been shown to be useful tumour markers in carcinomas of different organs [4, 9, 12]. The biosynthesis of these oligosaccharides are usually increased and altered during the acquisition of the malignant phenotype and tumour progression [5, 12]. Some studies refer that aberrant glycosylation is a result of initial oncogenic transformation, as well as a key event in induction of invasion and metastases [10, 12].

Most human carcinomas show changes within cell surface carbohydrates compared to their normal counterparts [4, 12].

sLex, present on the surface of tumour cells has been found to serve as ligands for endothelial E-selectin and was shown to play a major role in the process of adhesion of cancer cells to the endothelium [38]. sLex not only is a marker for cancer but also is functionally implicated in the malignant behaviour of cancer cells [4, 1214]. E-selectin, one of the selectin family member is expressed on the vascular endothelial cells and adheres to a carbohydrate ligand, sLex [15, 16]. Binding of sLex, present on the cell membrane of neutrophil granulocytes, to E-selectin, expressed on activated endothelial cells, was shown to initiate neutrophil extravasation and migration into tissues [15]. It has been hypothesized that the E-selectin/sLex interaction can mediate the sequence of adhesion of tumour cells to endothelium and their subsequent extravasation in a process that mimics the above process of inflammation [15, 17]. The sLex antigen is expressed by various human carcinomas such as: gastric carcinoma [26], colorectal carcinoma [25], lung cancer [22], prostate carcinoma [24], bladder carcinoma [8], oral [39], head&neck squamous cell carcinoma [40] and breast cancer [11, 20, 23]. The amounts of sLex expression are closely associated with progression and with poor prognosis in those cancers.

In canine cancers, Nakagawa et al has described the expression of sLex in canine and feline mammary gland tumours. However no association with clinicopathological features and prognosis was observed [29, 41].

The present study demonstrates that in malignant canine mammary tumours the malignant transformation of the mammary gland is accompanied by expression of sLex. These results are in agreement with previous observations showing that in squamous metaplasia, used as criteria of malignancy in canine mammary cancer [4244], there is a strong expression of sLexantigen. These observations support the use of sLex as a prognostic tumour marker in canine mammary carcinomas.

In this study, we found no significant relationship between sLex expression and the histological type of the tumours, classified according to World Health Organization classification. This result is in agreement with the results described by Nakagawa et al in canine and feline mammary gland tumours [29]. Similarly, in woman breast cancer, Nakagoe et al did not find an association between sLex expression and histological type of the carcinoma [20].

Previous studies have shown that, in woman breast cancer, tumour necrosis is associated with poorer survival [4547] and higher recurrence rates [46]. In canine mammary tumours, the presence of large areas of necrosis within the tumour mass could be used as criteria for a diagnosis of malignancy [44]. In spite of no association between sLex expression and tumour necrosis we observed that some tumours with necrosis showed high amounts of sLex expression.

It is clear that the expression of sLex in tumours is a marker of the invasive and/or metastatic properties of the tumours [4, 11]. In addition, it has been shown that sLex promotes binding of tumour cells at an invasion focus to endothelial cells through E-Selectin [11]. Many clinical studies show a clear association between the expression of sLex and tumours with enhanced progression and metastases [19]. In woman breast cancer, it was reported that the expression of sLex antigen in tumour cells was associated with poorer prognosis [20]. Matsuura et al demonstrated that the level of sLex was elevated in the sera of patients with metastatic breast cancers [21]. Still in woman breast cancer, Jeschke et al reports that overexpression of sLex was associated with poorer prognosis and malignant relapse [23].

To date, the expression of sLex in canine malignant mammary tumours, was not correlated neither with clinicopathological features, neither with prognoses [29].

In the present study we found a significant correlation between sLex expression and lymph node metastases. To the best of our knowledge, this is the first study to show such a relationship in canine malignant mammary tumours. These observations may suggest that sLex expression may also play a role in the process of local lymphatic invasion and metastization [38]. On the other hand, we did not observe an association between sLex expression and the development of distant metastases. This observation may suggest that in canine mammary tumours sLex does not contribute to haematogenous metastasis. However we could not rule out that the absence of association of sLex and haematogenous metastasis stems from the small number of cases studied for this clinicopathological feature.

These combined results from the relation between sLex expression and the clinicopathological features allow us to conclude that the sLex carbohydrate structure contributes for the malignant phenotype and tumour progression of canine malignant mammary tumours.

Tumour cell dissemination and development of metastases is a multistep process involving complex interaction between cancer cells, extracellular matrix, the vascular system, the immune system and the target organs [48]. Adhesion molecules are contributory factors toward metastatic activity. Adhesion can be divided into reduced adhesion of tumour cell, tumour cell interaction and increased adhesion of floating tumour cells to vascular endothelial cells [48]. Recently we and other authors have described that the loss of E-Cadherin expression may have prognostic value in canine malignant mammary tumours [33, 49]. In the present study, our results also showed that increasing expression of sLex correlates with lymph node metastases in canine mammary carcinomas. To address a possible cooperative role between these two molecules involved in cell adhesion, sLex and E-cadherin, we have compared their expression in canine malignant mammary tumours. Our results showed an inverse relationship between sLex and E-cadherin expression. Cases expressing sLex showed decrease E-Cadherin expression and vice-versa. Similarly, we could observe in doubled labelled immunofluorescence images, that cells that expressed sLex were negative for E-cadherin and vice-versa. This observation is the first indication of a significant relationship between sLex and E-cadherin expression in canine malignant mammary tumours. Based on our results it seems that the expression of sLex and/or E-cadherin on the same tumour cell could be regulated by an internal mechanism of the cell. In a previous study in a model of woman Inflammatory Breast Carcinoma (IBC), Alpaugh et al have described a cooperative role of E-cadherin overexpression and sLex underexpression in the genesis of the lymphovascular embolus of IBC [30, 31]. These results showed that both types of adhesion molecules might play opposing roles within the same tumour cell model. Furthermore, Jeschke et al have also shown, in breast cancer, a negative correlation between the expression of Sialyl Lewis antigens and E-cadherin as the risk of breast cancer metastasis progresses [23].

Our findings, in canine mammary carcinomas, supports the generally accepted dogma that metastatic propensity is an active biologic process that includes the decrease of tumour cells adhesion at the primary tumour site (E-cadherin down-regulation) which is thought to be accompanied by higher mobility and invasiveness [50] contributing to the process of local lymphatic invasion and metastization (sLex overexpression).

Conclusion

Our results demonstrate the importance of sLex in malignant phenotype of canine mammary carcinoma and support the use of sLex as a prognostic tumour marker in canine malignant mammary gland tumours.

The significant relation between sLex and lymph node metastases allow us to conclude that sLex can be used as prognostic factor in canine malignant mammary tumours.

There is an inverse relationship between the expression of the adhesion molecules sLex and E-cadherin, in canine mammary carcinomas.

The present results warrants further investigation addressing the clarification of the molecular mechanism determining this inverse correlation between sLex and E-cadherin as well as the investigation of the mechanisms by which sLex interferes with homotypic cellular adhesion mediated by E-cadherin in canine malignant mammary tumours, as a comparative model to woman breast cancer.

Abbreviations

sLex

Sialyl Lewis x

sLea

Sialyl Lewis a

HE: 

Haematoxylin and eosin

IHC: 

Immunohistochemistry

ABC: 

Avidin-biotin-peroxidase-complex

mAbs: 

Monoclonal antibodies

PBS: 

Phosphate buffered saline

BSA: 

Bovine serum albumin

DAB: 

3,3diaminobenzidinetetrahydrochloride

DAPI: 

4'-6-Diamidino-2-phenylindole

NS: 

Non significant

IBC: 

Inflammatory Breast Carcinoma

Declarations

Acknowledgements

Supported by Portuguese agency " Fundação para a Ciência e a Tecnologia, Programa Operacional Ciência e Inovação 2010 (POCI 2010) do Quadro Comunitário de Apoio III" and Project grant no. POCI/CVT/57795/2004.

SSP acknowledges FCT for financial support (SFRH/BD/21693/2005).

Authors’ Affiliations

(1)
Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP)
(2)
Institute of Biomedical Sciences of Abel Salazar (ICBAS), University of Porto, Largo Prof.
(3)
Medical Faculty, University of Porto, Alameda Prof. Hernâni Monteiro

References

  1. Sorenmo K: Canine mammary gland tumors. Vet Clin Small Anim. 2003, 33: 573-596. 10.1016/S0195-5616(03)00020-2.View ArticleGoogle Scholar
  2. Owen LN: A comparative study of canine and human breast cancer. Invest Cell Pathol. 1979, 2: 257-275.PubMedGoogle Scholar
  3. Kurzman ID, Gilbertson SR: Prognostic factors in canine mammary tumors. Seminars in Veterinary Medicine and Surgery (Small Animal). 1986, 1: 25-32.Google Scholar
  4. Kannagi R, Izawa M, Koike T, Miyazaki K, Kimura N: Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis. Cancer Sci. 2004, 95: 377-384. 10.1111/j.1349-7006.2004.tb03219.x.View ArticlePubMedGoogle Scholar
  5. Hakomori S: Tumour malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res. 1996, 56: 5309-5318.PubMedGoogle Scholar
  6. Borsig L, Wong R, Hynes RO, Varki NM, Varki A: Synergistic effects of l- and p-selectin in facilitating tumour metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc Natl Acad Sci. 2002, 99: 2193-2198. 10.1073/pnas.261704098.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Fukuda M: Possible roles of tumour-associated carbohydrate antigens. Cancer Res. 1996, 56: 2237-2244.PubMedGoogle Scholar
  8. Numahata K, Satoh M, Handa K, Saito S, Ohyama C, Ito A, Takahashi T, Hoshi S, Orikasa S, Hakomori S: Sialosyl-lex expression defines invasive and metastatic properties of bladder carcinoma. Cancer. 2002, 94: 673-685. 10.1002/cncr.10268.View ArticlePubMedGoogle Scholar
  9. Wang PH: Altered glycosylation in cancer: sialic acids and sialyltransferases. J Cancer Mol. 2005, 1: 73-81.Google Scholar
  10. Hakomori S: Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci. 2002, 99: 10231-10233. 10.1073/pnas.172380699.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Ono M, Hakomori S: Glycosylation defining cancer cell motility and invasiveness. Glycoconj J. 2004, 20: 71-78. 10.1023/B:GLYC.0000018019.22070.7d.View ArticlePubMedGoogle Scholar
  12. Dube DH, Bertozzi CR: Glycans in cancer and inflammation – potential for therapeutics and diagnostics. Nature Reviews. 2005, 4: 477-488. 10.1038/nrd1751.PubMedGoogle Scholar
  13. Monzavi-Karbassi B, Whitehead TL, Jousheghany F, Artaud C, Hennings L, Shaaf S, Slaughter A, Korourian S, Kelly T, Blaszczyk-Thurin M, Kieber-Emmons T: Deficiency in surface expression of e-selectin ligand promotes lung colonization in a mouse model of breast cancer. Int J Cancer. 2005, 117: 398-408. 10.1002/ijc.21192.View ArticlePubMedGoogle Scholar
  14. Ugorski M, Laskowska A: Sialyl lewisa: a tumour-associated carbohydrate antigen involved in adhesion and metastatic potential of cancer cells. Acta Bioch Polon. 2002, 49: 303-311.Google Scholar
  15. Magnani JL: The discovery, biology, and drug development of sialyl lea and sialyl le and lex. Arch Biochem Biophys. 2004, 426: 122-131. 10.1016/j.abb.2004.04.008.View ArticlePubMedGoogle Scholar
  16. Varki A: Selectin ligands. Proc Natl Acad Sci USA. 1994, 91: 7390-7397. 10.1073/pnas.91.16.7390.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Sawada R, Tsuboi S, Fukuda M: Differential E-selectin-dependent adhesion efficiency in sublines of a human colon cancer exhibiting distinct metastatic potentials. J Biol Chem. 1994, 269: 1425-1431.PubMedGoogle Scholar
  18. Kannagi R: Molecular mechanism for cancer-associated induction of sialyl Lewis X and sialyl Lewis A expression-The Warburg effect revisited. Glycoconjugate J. 2004, 20: 353-364. 10.1023/B:GLYC.0000033631.35357.41.View ArticleGoogle Scholar
  19. Dabelsteen E: Cell surface carbohydrates as prognostic markers in human carcinomas. J Pathol. 1996, 179: 358-369. 10.1002/(SICI)1096-9896(199608)179:4<358::AID-PATH564>3.0.CO;2-T.View ArticlePubMedGoogle Scholar
  20. Nakagoe T, Fukushima K, Itoyanagi N, Ikuta Y, Oka T, Nagayasu T, Ayabe H, Hara S, Ishikawa H, Minami H: Expression of abh/lewis-related antigens as prognostic factors in patients with breast cancer. J Cancer Res Clin Oncol. 2002, 128: 257-264. 10.1007/s00432-002-0334-5.View ArticlePubMedGoogle Scholar
  21. Matsuura N, Narita T, Mitsuoka C, Kimura N, Kannagi R, Imai T, Funahashi H, Takagi H: Increased level of circulating adhesion molecules in the sera of breast cancer patients with distant metastases. Jpn J Clin Oncol. 1997, 27: 135-139. 10.1093/jjco/27.3.135.View ArticlePubMedGoogle Scholar
  22. Yu CJ, Shih JY, Lee YC, Shun CT, Yuan A, Yang PC: Sialyl lewis antigens: association with muc5ac protein and correlation with post-operative recurrence of non-small cell lung cancer. Lung Cancer. 2005, 47: 59-67. 10.1016/j.lungcan.2004.05.018.View ArticlePubMedGoogle Scholar
  23. Jeschke U, Mylonas I, Shabani N, Kunert-Keil C, Schindlbeck C, Gerber B, Friese K: Expression of sialyl lewis x, sialyl lewis a, e-cadherin and cathepsin-d in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis. Anticancer Res. 2005, 25: 1615-1622.PubMedGoogle Scholar
  24. Jorgensen T, Berner A, Kaalhus O, Tveter KJ, Danielsen HE, Bryne M: Up-regulation of the oligosaccharide Sialyl Lewisx : a new prognostic parameter in metastatic prostate cancer. Cancer Res. 1995, 55: 1817-1819.PubMedGoogle Scholar
  25. Grabowski P, Mann B, Mansmann U, Lövin N, Foss HD, Berger G, Scherübl H, Riecken EO, Buhr HJ, Hanski C: Expression of Sialyl-Lex antigen defined by Mab AM-3 is an independent prognostic marker in colorectal carcinoma patients. Int J Cancer. 2000, 88: 281-286. 10.1002/1097-0215(20001015)88:2<281::AID-IJC21>3.0.CO;2-2.View ArticlePubMedGoogle Scholar
  26. Ura H, Denno R, Hirata K, Yamaguchi K, Yasoshima T, Shishido T: Close correlation between increased sialyl-lewisx expression and metastasis in human gastric carcinoma. World J Surg. 1997, 21: 773-776. 10.1007/s002689900304.View ArticlePubMedGoogle Scholar
  27. Amado M, Carneiro F, Seixas M, Clausen H, Sobrinho-Simões M: Dimeric Sialyl-Lex expression in gastric carcinoma correlates with venous invasion and poor outcome. Gastroenterology. 1998, 114: 462-470. 10.1016/S0016-5085(98)70529-3.View ArticlePubMedGoogle Scholar
  28. Futamura N, Nakamura S, Tatematsu M, Yamamura Y, Kannagi R, Hirose H: Clinicopathologic significance of sialyl Lex expression in advanced gastric carcinoma. Br J Cancer. 2000, 83: 1681-1687. 10.1054/bjoc.2000.1484.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Nakagawa T, Uyama R, Ohashi E, Takahashi T, Hong SH, Mochizuki M, Matsunaga S, Nishimura R, Sasaki N: The expression of sialyl lewis x in canine and feline mammary gland tumors. J Vet Med Sci. 2002, 64: 949-952. 10.1292/jvms.64.949.View ArticlePubMedGoogle Scholar
  30. Alpaugh ML, Tomlinson JS, Kasraeian S, Barsky SH: Cooperative role of e-cadherin and sialyl-lewis x/a-deficient muc1 in the passive dissemination of tumour emboli in inflammatory breast carcinoma. Oncogene. 2002, 21: 3631-3643. 10.1038/sj.onc.1205389.View ArticlePubMedGoogle Scholar
  31. Alpaugh ML, Tomlinson JS, Ye Y, Barsky SH: Relationship of sialyl-lewisx/a underexpression and e-cadherin overexpression in the lymphovascular embolus of inflammatory breast carcinoma. Am J Pathol. 2002, 161: 619-628.View ArticlePubMedPubMed CentralGoogle Scholar
  32. Alpaugh ML, Barsky SH: Reversible model of spheroid formation allows for high efficiency of gene delivery ex vivo and accurate gene assessment in vivo. Hum Gene Ther. 2002, 13: 1245-1258. 10.1089/104303402320139023.View ArticlePubMedGoogle Scholar
  33. Matos AJF, Lopes C, Carvalheira J, Santos M, Rutteman GR, Gärtner F: E-cadherin expression in canine malignant mammary tumours: relationship to other clinico-pathological variables. J Comp Path. 2006, 134: 182-189. 10.1016/j.jcpa.2005.10.004.View ArticlePubMedGoogle Scholar
  34. Misdorp W, Else RW, Hellmén E, Lipscomb TP: Histological classification of the mammary tumours of the dog and the cat. World Health Organization International Histological Classification of Tumours of Domestic Animals. Edited by: Shulman FI. 1999, Armed Forces Institute of Pathology, Washington DC, 16-29.Google Scholar
  35. Hsu SM, Faine L, Fanger H: A comparative study of the peroxidase-antiperoxidase method and the avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol. 1981, 75: 734-738.View ArticlePubMedGoogle Scholar
  36. Fukushi Y, Nudelman E, Levery SB, Hakomori S, Rauvala H: Novel fucolipids accumulating in human adenocarcinoma: III a hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside (VI3 NeuAcV3 III3 Fuc2 nLc 6). J Biol Chem. 1984, 259: 10511-10517.PubMedGoogle Scholar
  37. SAS Institute Inc: SAS/STAT® User's Guide, Version 6. 1989, Cary, NC: SAS Institute Inc, 1: 943-FourthGoogle Scholar
  38. Kannagi R: Carbohydrate-mediated cell adhesion involved in hematogenous metastasis of cancer. Glycoconj J. 1997, 14: 577-584. 10.1023/A:1018532409041.View ArticlePubMedGoogle Scholar
  39. Kurahara S, Shinohara M, Ikebe T, Nakamura S, Hiraki A, Sasaki M, Beppu M, Shirasuna K: Immunohistochemical study of sialyl lea and sialyl lex antigen in oral squamous cell carcinoma: the association of sialyl lea expression with the metastatic potential. Head Neck. 1999, 21: 330-337. 10.1002/(SICI)1097-0347(199907)21:4<330::AID-HED7>3.0.CO;2-#.View ArticlePubMedGoogle Scholar
  40. Farmer RW, Richtsmeier WJ, Scher RL: Identification of sialyl lewis-x in squamous cell carcinoma of head and neck. Head Neck. 1998, 20: 726-731. 10.1002/(SICI)1097-0347(199812)20:8<726::AID-HED11>3.0.CO;2-C.View ArticlePubMedGoogle Scholar
  41. Nakagawa T, Watanabe M, Ohashi E, Uyama R, Takauji S, Mochizuki M, Nishimura R, Ogawa H, Sugano S, Sasaki N: Cyclopedic protein expression analysis of cultured canine mammary gland adenocarcinoma cells from six tumours. Res Vet Sci. 2006, 80: 317-323. 10.1016/j.rvsc.2005.07.011.View ArticlePubMedGoogle Scholar
  42. Peña L, Perez-Alenza D, Rodriguez-Bertos A, Nieto A: Canine inflammatory mammary carcinoma: histopathology, immunohistochemistry and clinical implications of 21 cases. Breast Cancer Res Treat. 2003, 78: 141-148. 10.1023/A:1022991802116.View ArticlePubMedGoogle Scholar
  43. Benjamin SA, Lee AC, Saunders WJ: Classification and behaviour of canine mammary epithelial neoplasms based on life-span observations in beagles. Vet Pathol. 1999, 36: 423-436. 10.1354/vp.36-5-423.View ArticlePubMedGoogle Scholar
  44. Bostock DE: The prognosis following the surgical excision of canine mammary neoplasms. Europ J Cancer. 1975, 11: 389-396.View ArticleGoogle Scholar
  45. Parham DM, Hagen N, Brown RA: Simplified method of grading primary carcinomas of the breast. J Clin Pathol. 1992, 45: 517-520. 10.1136/jcp.45.6.517.View ArticlePubMedPubMed CentralGoogle Scholar
  46. Gilchrist KW, Gray R, Fowble B, Tormey DC, Taylor SG: Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node-positive cancer: a 10-year follow-up study of 728 Eastern Cooperative Oncology Group patients. J Clin Oncol. 1993, 11: 1929-1935.PubMedGoogle Scholar
  47. Carlomagno C, Perrone F, Lauria R, de Laurentiis M, Gallo C, Morabito A, Pettinato G, Panico L, bellelli T, Apicella A: Prognostic significance of necrosis, elastosis, fibrosis and inflammatory cell reaction in operable breast cancer. Oncology. 1995, 52: 272-277.View ArticlePubMedGoogle Scholar
  48. Liotta LA, Stetler-Stevenson WG, Steeg PS: Cancer invasion and metastasis: positive and negative regulatory elements. Cancer Invest. 1991, 9: 543-551.View ArticlePubMedGoogle Scholar
  49. Brunetti B, Sarli G, Preziosi R, Monari I, Benazzi C: E-Cadherin expression in canine mammary carcinomas with regional lymph node metastases. J Vet Med. 2003, 50: 496-500. 10.1111/j.1439-0442.2003.00577.x.View ArticleGoogle Scholar
  50. Birchmeier W, Behrens J: Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta. 1994, 1198: 11-26.PubMedGoogle Scholar
  51. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/7/124/prepub

Copyright

© Pinho et al; licensee BioMed Central Ltd. 2007

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement